Extended treatment study for complex regional pain syndrome
Part of Brain & nervous system, Pain clinical trials.
This study gives an extended course of neridronate infusions to people who completed the earlier AMBTX-01-301 trial, to see if longer treatment safely keeps easing their chronic pain and other symptoms of complex regional pain syndrome (a long-lasting pain condition, often after an injury).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You took part in the earlier neridronate study and finished the 12-week check.
- You have ongoing moderate-to-severe pain or other CRPS symptoms that need more treatment.
- You are willing to receive 4 more infusions through a vein and have follow-up safety tests.
- Your kidney function must be good, and you must not have had certain other bone or pain treatments recently.
- If you can become pregnant, you must use effective birth control during treatment and for 6 months after.
- You must be able to give informed consent and follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if an intravenous medicine called AMBTX-01 (neridronate) can help people with early-stage Complex Regional Pain Syndrome (CRPS) type 1. It focuses on those whose affected limb feels warm, looks red, and is swollen.
This trial tests whether a low dose of naltrexone, a medication that may help calm overactive immune and pain signals, can reduce pain and improve daily life in people with complex regional pain syndrome (CRPS), a chronic condition that often causes severe pain and swelling.
This study is a registry that tracks people with Complex Regional Pain Syndrome (CRPS) who already received neridronate infusions in a previous trial. It looks at how they do over the long term to learn more about the treatment's lasting effects.
This study tests whether a conservative treatment plan can help people with complex regional pain syndrome (CRPS), a condition where pain lasts longer than expected after an injury. You may qualify if you have had CRPS symptoms for up to 5 years and are between ages 18 and 70.
This trial tests whether low-dose naltrexone can reduce symptoms of complex regional pain syndrome (CRPS), a long-lasting pain condition in an arm or leg. It may help by targeting pain signaling, but you must meet specific CRPS diagnosis and medication rules to join.
This study tests a high-CBD cannabis extract (BRC-002) to see if it can help reduce pain and improve health in people with Complex Regional Pain Syndrome (CRPS). Participants will not use opioids or other cannabis during the study.
Hear when a new Complex Regional Pain Syndrome Type I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.